Bristol Myers Squibb Stock: Analyst Estimates & Ratings The pharmaceutical industry has long been a barometer for global economic trends. Bristol Myers Squibb (BMY), based in New Jersey, is no exception.
Its stock has surged over the past year, outpacing even the broader S&P 500 Index. One key driver behind BMY's success is its ability to deliver consistently strong earnings reports.
In April, the company reported better than expected Q1 2026 results, with revenue rising 2. 6% from the prior year and adjusted EPS coming in at $1. 58 per share.